MannKind reported $411.7M in Assets for its fiscal quarter ending in June of 2025.




Assets Change Date
Adma Biologics USD 558.38M 69.7M Jun/2025
Dynavax Technologies USD 918.45M 27.48M Jun/2025
Eli Lilly USD 100.92B 11.53B Jun/2025
Halozyme Therapeutics USD 2.05B 142.63M Jun/2025
Insmed USD 2.48B 677.12M Jun/2025
MacroGenics USD 245.42M 16.24M Jun/2025
MannKind USD 411.7M 1.56M Jun/2025
Merck USD 117.52B 2.4B Jun/2025
Novo Nordisk DKK 489.16B 91.72B Mar/2025
Pfizer USD 206.1B 1.93B Jun/2025
Sanofi EUR 124.96B 6.93B Jun/2025
Xencor USD 879.42M 25.26M Jun/2025